yahoo_financeOriginal article
FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer
RegulatoryapprovedKeytrudaPadcevPositive
AI Analysis
Summary
The FDA has expanded the approved use of the Keytruda-Padcev combination therapy for bladder cancer, representing a label expansion for the jointly developed treatment by Merck and Pfizer.
Outcome Details
FDA expanded approval for Keytruda-Padcev combination in bladder cancer
Importance:7/10
Sentiment:
0.80
FDA approvallabel expansiononcologycombination therapybladder cancerimmunotherapy
Read the original article
Published by yahoo_finance on July 13, 2026 3:08 PM